Hypertension (29 patients), diabetes mellitus (23 patients), ischemic heart disease (5 patients), and other conditions (15 patients) were the primary comorbidities for patients with stage IV GC treated with HER2 inhibitors in combination with chemotherapy (18%), immune checkpoint inhibitors (15%), inhibitors of MET proto-oncogene, receptor tyrosine kinase (MET) or vascular endothelial growth factor (VEGFR)2 (5%), and first-line capecitabine/oxaliplatin (62%) [74]. Here, MET is linked to coronary artery disorder.